Investor, Andy Smith, reviews some of the learnings from cancer
clinical trials and examples of what investors have learnt from
compounds in development and a paradox in oncology clinical trials.
Companies mentioned in this talk will include AstraZeneca, OSI
Pharma and Antisoma.
Continuing a series of expert analysis and commentary on the Healthcare sector. Join the discussion and leave your comments and feedback for more on this and other upcoming Global Healthcare sector topics.